Microsoft Offers Rebate Deal on Previously Owned iPads and 2 Other Dow Movers to Watch

Microsoft Corp. (NASDAQ:MSFT): Current price $32.93

Microsoft now offers rebates of $200 or more for traded-in Apple iPads when a new Surface tablet is purchased. The two-step plan is outlined by the company’s policy: when customers bring in a ”gently used” iPad 2, 3 or 4, you can get a minimum of a $200 gift card to the Microsoft store. At that point, they then choose a Surface RT, Surface Pro or any other “cool products” at the Microsoft store. The plan is said be centered around getting rid of rival older iPads, while emptying warehouses of the 2012 Surface models so as to make room for the new Surface products that should be debuted in New York on September 23.

msft-20130913

JPMorgan Chase & Co. (NYSE:JPM): Current price $52.69

The ex-JPMorgan trader Julien Grout, who is charged with attempting to conceal the bank’s record trading loss in 2012, is telling prosecutors that he was following orders from his then-boss, Bruno Iksil, according to knowledgeable sources. They explained that Grout’s lawyers have supplied records including e-mails to United States prosecutors in Manhattan during the past two weeks in order to cast doubt on the government’s stand that Iksil resisted pressure to inflate the value of the trades.

Grout and another supervisor, Javier Martin-Artajo, have been charged with conspiracy and wire fraud, but at the same time, Iksil averted prosecution by agreeing to cooperate with authorities. While announcing charges against Grout and Martin-Artajo in August, United States Attorney Preet Bharara in Manhattan said that Iksil had sounded the alarm “more than once” to co-workers.

jpmm-20130913

Johnson & Johnson (NYSE:JNJ): Current price $88.50

J&J has brought a lawsuit against a division of Boehringer Ingelheim Gmbh, concerning whether a dispute regarding an agreement to produce the cancer drug Doxil must be submitted to arbitration. Attorneys for J&J contend that executives of Boehringer’s United States business violated a 2009 accord to make Doxil, used to treat ovarian cancer, and left J&J hurrying to meet demand say court filings unsealed in Delaware Chancery Court in Wilmington. In an edited version of the complaint filed on Friday, J&J said that “BI’s breach of the agreement cannot be seriously disputed.”

jnj-20130913

Don’t Miss: J&J Pulls Another Med Off the Shelves; This Time, a Schizophrenia Drug.

More from The Cheat Sheet